Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective boosted by equities researchers at Wells Fargo & Company from $113.00 to $121.00 in a report issued on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. Wells Fargo & Company‘s target price indicates a potential upside of 12.91% from the company’s previous close.
A number of other equities analysts have also weighed in on the company. Raymond James Financial boosted their price objective on Edwards Lifesciences from $100.00 to $103.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. BTIG Research raised their target price on Edwards Lifesciences from $110.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Wall Street Zen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Sunday, November 8th. Deutsche Bank set a $104.00 price target on shares of Edwards Lifesciences in a research report on Tuesday, October 27th. Finally, Rothschild & Co Redburn boosted their price target on shares of Edwards Lifesciences from $99.00 to $102.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Twenty-three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $109.88.
View Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Trading Up 0.0%
Shares of Edwards Lifesciences stock opened at $107.16 on Monday. The stock has a market cap of $61.62 billion, a P/E ratio of 60.54, a P/E/G ratio of 2.86 and a beta of 0.85. The stock’s 50 day simple moving average is $90.42 and its 200-day simple moving average is $86.32. Edwards Lifesciences has a 1-year low of $74.66 and a 1-year high of $107.69. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.60 and a quick ratio of 3.86.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The business had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. During the same period in the prior year, the business earned $0.67 earnings per share. The business’s revenue was up 10.5% compared to the same quarter last year. Analysts predict that Edwards Lifesciences will post 3.01 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, VP Donald E. Bobo, Jr. sold 48,900 shares of the firm’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $103.05, for a total transaction of $5,039,145.00. Following the completion of the sale, the vice president directly owned 22,798 shares of the company’s stock, valued at approximately $2,349,333.90. This trade represents a 68.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 53,945 shares of company stock worth $5,498,306. Company insiders own 0.31% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. Empirical Finance LLC increased its position in shares of Edwards Lifesciences by 2.2% during the third quarter. Empirical Finance LLC now owns 21,705 shares of the medical research company’s stock valued at $1,874,000 after acquiring an additional 459 shares during the last quarter. Entropy Technologies LP acquired a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $5,204,000. Jump Financial LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $2,662,000. Flputnam Investment Management Co. boosted its position in shares of Edwards Lifesciences by 47.8% during the 3rd quarter. Flputnam Investment Management Co. now owns 7,437 shares of the medical research company’s stock worth $642,000 after purchasing an additional 2,406 shares during the period. Finally, L2 Asset Management LLC boosted its position in shares of Edwards Lifesciences by 4.2% during the 3rd quarter. L2 Asset Management LLC now owns 3,625 shares of the medical research company’s stock worth $313,000 after purchasing an additional 146 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
Further Reading
- Five stocks we like better than Edwards Lifesciences
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
